Tagged with GEN

UK A British success story, Clinigen Group provides companies with services in portfolio and product lifecycle management on a global basis. Its CEO, Shaun Chilton, talks to us about the value proposition of Clinigen, what makes it unique and why competition is more flattering than threatening.   Clinigen’s value proposition is…

Portugal Mario Madeira, general manager of Teva Portugal, highlights the milestones of the affiliate in Portugal, referencing the economic crisis and where Teva is now positioned in the country. In addition, he comments on Portugal’s great potential for digitalizing its healthcare sector. What are Teva Portugal’s priorities for 2018? “Teva is…

UK Heading Accord Healthcare’s European, Middle East and North African operations, James Burt highlights the rapid growth the company has achieved within the region and how it has reached an impressive double-digit market share in the UK, putting Accord firmly on track to attain their goal of becoming a top 5…

UK Promoting the UK’s capital in times of Brexit, Laura Citron, CEO at London & Partners, the international promotional agency of the Mayor of London, stresses the critical importance life sciences hold as a sector for the city’s economy. With its potential to create good jobs improving the live of Londoners,…

Portugal Experienced country manager, João Madeira, introduces Mylan’s new vision to be a global healthcare company serving patients across the world with their hybrid generic, OTC and innovative pharmaceutical business model which in the same breath sustains and innovates the healthcare system. Touching on themes of talent, biosimilars, and Portugal as…

Spain Joaquin Rodrigo, general director of Sandoz Spain and Portugal, introduces the company’s highly diversified generics and biosimilars portfolio in the region, gives his thoughts on Spain’s generics market, and outlines the rationale behind the creation of a national biosimilars association, BioSim.   Can you please start by introducing Sandoz and…

Spain Spanish biotech ALGENEX is using insect pupae to develop high-purity vaccines more quickly and at a lower cost than conventional production methods. Having secured further investment from outside of Spain, ALGENEX is now looking to produce its first vaccine for European regulators using insect-based production methods. We realised the huge…

UK As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical industry and the patients who rely on it are under serious threat from Brexit” Erik Nordkamp, Pfizer Erik Nordkamp, the…

China Sheng Sitong, founder and CEO of gene sequencing device company, Considerin Group (formerly HYK Gene), discusses Considerin’s rapid expansion and the development of precision medicine in China. Mr. Sheng, could you briefly introduce your company, Considerin Group, to our international audience? “We are the only Chinese company to have our…

Spain Carlos Teixeira, CEO of Teva Spain and Portugal, discusses the challenges the generic sector is facing in Spain, which ultimately spurred the company towards other business opportunities, and highlights the significant footprint of the Spanish affiliate, with its manufacturing site in Zaragoza serving as an export base for Europe and…

Pharma In May 2018, PharmaBoardroom’s readers were asked what they felt were the biggest new sources of disruption to the traditional pharma industry today. Options included 3D Bioprinting, blockchain storage, genomics and artificial intelligence. 3D Bioprinting As Figure 1 (below) shows, 11 percent of our survey respondents felt that 3D bioprinting…

Spain Jose Escribano, founder of Spanish biotech success story ALGENEX, discusses the company’s focus on using insects in its research, difficulties in accessing capital, and its future growth strategy. Can you please start by describing the opportunities that presented themselves, allowing you to create ALGENEX? “What we have done is to…